Cargando…
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
Background. The MammaPrint (MP) diagnostic assay stratifies breast cancer patients into high- and low-risk groups using mRNA analysis of a 70-gene profile. The assay is validated for assessment of patients with estrogen receptor positive or negative tumors less than 5 cm with 3 or fewer malignant ly...
Autores principales: | Espinel, C. Francisco, Keating, Shaughn, Hibshoosh, Hanina, Taback, Bret, Joseph, Kathie-Ann, El-Tamer, Mahmoud, Feldman, Sheldon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820467/ https://www.ncbi.nlm.nih.gov/pubmed/24278759 http://dx.doi.org/10.6064/2012/942507 |
Ejemplares similares
-
Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016) -
Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016) -
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017) -
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020) -
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021)